Kamada Ltd. announced it obtained a tax ruling from the Israel Tax Authority regarding its previously declared cash dividend of $0.17 per share, totaling approximately $9.8 million. The payment is scheduled for September 17, 2026, to shareholders of record as of August 27, 2026. Under the ruling, Nasdaq-listed shareholders residing in countries with tax treaties may apply for a reduced withholding tax rate by submitting documentation to processing agent IBI Trust Management by October 7, 2026. Israeli corporate shareholders may be eligible for an exemption from withholding tax. Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies and marketed products for rare conditions.
